Year: 2022
Type: editorial
Abstract: A trial fibrillation (AF) serves as an independent predictor of decreased quality of life, morbidity, and mortality in select patient populations. 1 As the most common arrhythmia, AF affects an estimated 46.3 million individuals worldwide, and diagnoses of new AF have become increasingly frequent owing to improved public health awareness and enhanced detection from ambulatory electrocardiographic monitoring.2,3 The medical field has met the growing AF population with the creation and refinement of the armamentarium of AF therapies.In the wake of increasing numbers of patients with AF and treatment options, there is an imperative need for studies to guide the selection of appropriate treatments within this vastly heterogeneous patient population.
Source: Circulation
Authors: Eunice Yang, Hugh Calkins
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4295471875